plerixafor
plerixafor: 10 clinical trials tracked.
plerixafor evidence translation
What we can confirm
10 tracked trials
What it means
What to watch
Prepared research question
What is verified about plerixafor, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 1 study sponsors
Clinical Trial Registry Records (10)
Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders
Primary endpoint: Incidence of treatment-emergent adverse events following filgrastim plus plerixafor administration
Phase 1/2 Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy
Primary endpoint: Quantify frequency and severity of adverse events (AEs) related to study agent from infusion to 12 months after infusion.
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
Primary endpoint: Safety and adverse events (AEs)
A Phase I/II Pilot Study of Memory-like NK Cells to Consolidate TCRαβ T Cell Depleted Haploidentical Transplant in High-risk AML
Primary endpoint: Safety of patients being administered donor-derived ML NK cells following TCR alpha beta depleted haploidentical cell transplant
Phase 1/2 Trial of Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-linked Chronic Granulomatous Disease
Primary endpoint: To evaluate the safety of base-edited autologous CD34+ cells
A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease
Primary endpoint: Percentage of Participants who are Alive at Post-transplantation Day 100
A Follow-Up Study to Add Whole Brain Radiotherapy (WBRT) to Standard Temozolomide Chemo-Radiotherapy in Newly Diagnosed Glioblastoma (GBM) Treated With 4 Weeks of Continuous Infusion Plerixafor
Primary endpoint: Proportion of Progression Free Survival Participants (PFS) at Six Months
A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Primary endpoint: progression-free survival (PFS)
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Primary endpoint: To mobilize CD34+ HPCs in ICL patients and healthy volunteers for collection and transfer into immunocompromised mice to investigate thymic development, survival, and trafficking of these cells in murine lymphoid and non-lymphoid organs
Phase I/II Study of Cellular Immunotherapy Using Central Memory-Enriched CD8+ T Cells Lentivirally Transduced to Express A CD19-Specific Chimeric Immunoreceptor Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
Primary endpoint: Number of Participants With Dose Limiting Toxicities (DLTs)